VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP)
NCT ID: NCT05379023
Last Updated: 2025-12-31
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
116 participants
INTERVENTIONAL
2022-06-27
2024-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Face-to-face evaluation (FF), TeleNP evaluation
In-Person (standard of care) Modality completed first, Telehealth Modality completed second
Face-to-face evaluation (FF)
The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
TeleNP evaluation
The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
TeleNP evaluation, Face-to-face evaluation (FF)
Telehealth Modality completed first, In-Person (standard of care) Modality completed second
Face-to-face evaluation (FF)
The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
TeleNP evaluation
The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
Care Partners
Care Partners did not undergo the intervention; they completed outcome measures (surveys) of acceptability only.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Face-to-face evaluation (FF)
The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
TeleNP evaluation
The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals must carry a diagnosis of either suspected typical AD or atypical AD, based on the referring neurologist's diagnosis.
Exclusion Criteria
* Individuals who are legally blind or deaf, due to the auditory and visual components of the study.
* Individuals with a brain tumor and individuals who have a confirmed nonAD neurological diagnosis (e.g, Multiple Sclerosis; FTD).
* Individuals who are being evaluated outside of the UCH Memory Disorders Clinic.
* Individuals who report active (i.e., within the last 6 months) substance use of illicit drugs such as cocaine or methamphetamines, or who carry a diagnosis of a major psychiatric disorder (e.g., schizophrenia; bipolar disorder).
Note that care partners (3rd arm) did not undergo the intervention and there were no additional eligibility requirements for them except that they were involved in the patient's care
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brianne Bettcher, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Anschutz Medical Campus (CU-AMC)
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-5037
Identifier Type: -
Identifier Source: org_study_id